SCHEMBL1340537

SCHEMBL1340537

CSc1sc(NC(=O)C(=O)Nc2ccccc2C(=O)C2CCCC2)nc1CNS(C)(=O)=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.36
ALDH1A1 P00352 7/20 0.35
KDM4E B2RXH2 3/20 0.35
HPGD P15428 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35
RXFP1 Q9HBX9 2/20 0.35
CLK1 P49759 1/20 0.34
MAPT P10636 4/20 0.33
TP53 P04637 2/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
THRB P10828 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
FBP1 P09467 1/20 0.33
LMNA P02545 3/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
ALOX12 P18054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2648842 0.95 RORC (0.33) RORCALDH1A1KDM4EHPGDNPSR1
SCHEMBL1343411 0.93 ALDH1A1 (0.37) RORCALDH1A1KDM4EHPGDNPSR1
SCHEMBL1343069 0.92 RORC (0.39) RORCALDH1A1KDM4EHPGDNPSR1
SCHEMBL1342883 0.90 CLK1 (0.34) ALDH1A1CLK1MAPTTP53KMT2A
SCHEMBL1341995 0.89 CLK1 (0.37) RORCALDH1A1KDM4EHPGDNPSR1
SCHEMBL2648840 0.89 RORC (0.30) RORC
SCHEMBL1341818 0.88 RORC (0.36) RORCALDH1A1KDM4EHPGDNPSR1
SCHEMBL1342180 0.88 RORC (0.36) RORCALDH1A1KDM4EHPGDNPSR1
SCHEMBL1343535 0.87 GRM4 (0.35) RORCALDH1A1KDM4EHPGDNPSR1
SCHEMBL2649976 0.87 RORC (0.36) RORCALDH1A1KDM4EHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 RORC 732/4885ALDH1A1 192/4885KDM4E 992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.